# Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children

> **NCT00287105** · PHASE2 · COMPLETED · sponsor: **Rennes University Hospital** · enrollment: 49 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Philadelphia Chromosome

## Interventions

- **DRUG:** Standard chemotherapy + Imatinib

## Key facts

- **NCT ID:** NCT00287105
- **Lead sponsor:** Rennes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2016-03-30
- **Final completion:** 2017-03-03
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2023-05-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00287105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00287105, "Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00287105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*